ES2184069T3 - Acidos beta-sulfonamidohidroxamicos como inhibidores de las metaloproteinasas de la matriz y de la tace. - Google Patents
Acidos beta-sulfonamidohidroxamicos como inhibidores de las metaloproteinasas de la matriz y de la tace.Info
- Publication number
- ES2184069T3 ES2184069T3 ES97912674T ES97912674T ES2184069T3 ES 2184069 T3 ES2184069 T3 ES 2184069T3 ES 97912674 T ES97912674 T ES 97912674T ES 97912674 T ES97912674 T ES 97912674T ES 2184069 T3 ES2184069 T3 ES 2184069T3
- Authority
- ES
- Spain
- Prior art keywords
- inhibitors
- tace
- matrix
- insistration
- chr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 title abstract 2
- 239000011159 matrix material Substances 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 206010015943 Eye inflammation Diseases 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010025421 Macule Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010029216 Nervousness Diseases 0.000 abstract 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 abstract 1
- 208000021386 Sjogren Syndrome Diseases 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 239000000061 acid fraction Substances 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 201000001474 proteinuria Diseases 0.000 abstract 1
- 230000000472 traumatic effect Effects 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 1
- 230000036269 ulceration Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE AL DESCUBRIMIENTO DE NUEVOS INHIBIDORES NO PEPTIDICOS, DE BAJO PESO MOLECULAR, DE LAS METALOPROTEINASAS DE LA MATRIZ (P.EJ. GELATINASAS, ESTROMELISINAS Y COLAGENASAS) Y DE LA ENZIMA CONVERTIDORA DE TNF- AL (TACE, ENIMA CONVERTIDORA DEL FACTOR- AL DE NECROSIS TUMORAL), LOS CUALES SON UTILES PARA EL TRATAMIENTO DE ENFERMEDADES EN LAS CUALES ESTAN IMPLICADAS DICHAS ENZIMAS, COMO ARTRITIS, CRECIMIENTO TUMORAL Y METASTASIS, ANGIOGENESIS, ULCERACION TISULAR, CICATRIZACION ANORMAL DE UNA HERIDA, ENFERMEDAD PERIODONTAL, ENFERMEDAD OSEA, PROTEINURIA, ANEURISMA AORTICO, PERDIDA DE CARTILAGO DEGENERATIVA RESULTANTE DE UNA LESION ARTICULAR TRAUMATICA, ENFERMEDADES DESMIELINIZANTES DEL SISTEMA NERVIOSO CENTRAL, RECHAZO DE INJERTOS, CAQUEXIA, ANOREXIA, INFLAMACION, FIEBRE, RESISTENCIA A INSULINA, CHOQUE SEPTICO, INSUFICIENCIA CARDIACA CONGESTIVA, ENFERMEDAD INFLAMATORIA DEL SISTEMA NERVIOSO CENTRAL, SINDROME DEL COLON IRRITABLE, INFECCION POR VIH, DEGENERACION MACULAR RELACIONADA CON LA EDAD, RETINOPATIA DIABETICA, VITREORRETINOPATIA DIABETICA, RETINOPATIA DE PREMATURIDAD, INFLAMACION OCULAR, QUERATOCONO, SINDROME DE SJOGREN, MIOPIA, TUMORES OCULARES, ANGIOGENESIS/NEOVASCULARIZACION OCULAR. LOS ACIDOS ORTOSULFONAMIDO HIDROXAMICOS DE LA PRESENTE INVENCION, INHIBIDORES DE TACE Y MMP, SE REPRESENTAN MEDIANTE LA FORMULA (1), DONDE LA FRACCION DE ACIDO HIDROXAMICO Y LA FRACCION SULFONAMIDO ESTAN UNIDAS A LOS CARBONOS ADYACENTES DEL GRUPO A, DONDE: A ES UN ANILLO HETEROCICLICO NO AROMATICO MONOCICLICO, DE 5 A 7 MIEMBROS, QUE TIENE DE 1 A 2 HETEROATOMOS SELECCIONADOS INDEPENDIENTEMENTE A PARTIR DE N, O Y S, OPCIONALMENTE SUSTITUIDO POR R 1 , R 2 , R 3 , Y R 4 ; UN CICLOALQUILO C 3 - C 7 QUE CONTIENE 0-2 ENLACES DOBLES Y SUSTITUIDO OPCIONALMENTE POR R 1 , R 2 , R 3 Y R 4 ; O - CHR 5 = CHR 6 -; Y Z, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 Y R 9 SE DESCRIBEN EN LA DESCRIPCION. SE INCLUYEN ASIMISMO LAS SALES FARMACEUTICAMENTE ACEPTABLES DE DICHOS COMPUESTOS, Y SUS ISOMEROS OPTICOS O DIASTEREOMEROS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72935996A | 1996-10-16 | 1996-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2184069T3 true ES2184069T3 (es) | 2003-04-01 |
Family
ID=24930685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES97912674T Expired - Lifetime ES2184069T3 (es) | 1996-10-16 | 1997-10-08 | Acidos beta-sulfonamidohidroxamicos como inhibidores de las metaloproteinasas de la matriz y de la tace. |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0934259B1 (es) |
| JP (1) | JP2001502326A (es) |
| KR (1) | KR20000049198A (es) |
| CN (1) | CN1105101C (es) |
| AR (1) | AR008676A1 (es) |
| AT (1) | ATE224364T1 (es) |
| AU (1) | AU736134B2 (es) |
| BR (1) | BR9712524A (es) |
| CA (1) | CA2268895A1 (es) |
| DE (1) | DE69715647T2 (es) |
| DK (1) | DK0934259T3 (es) |
| ES (1) | ES2184069T3 (es) |
| IL (1) | IL129149A (es) |
| NZ (1) | NZ335053A (es) |
| PT (1) | PT934259E (es) |
| WO (1) | WO1998016506A1 (es) |
| ZA (1) | ZA979236B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69917124T2 (de) * | 1998-04-10 | 2005-05-12 | Pfizer Products Inc., Groton | Cyclobutyl-Aryloxysulfonylamin-Hydroxamsäurederivate |
| WO1999065867A1 (en) * | 1998-06-17 | 1999-12-23 | Du Pont Pharmaceuticals Company | Cyclic hydroxamic acids as metalloproteinase inhibitors |
| US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
| US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
| US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
| US6358980B1 (en) | 1999-01-27 | 2002-03-19 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
| US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
| US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
| US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
| US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
| US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
| US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
| AU2320500A (en) * | 1999-02-02 | 2000-08-25 | Shionogi & Co., Ltd. | Sulfonamide derivatives having cyclic structures |
| ATE384756T1 (de) * | 2000-05-23 | 2008-02-15 | Ge Osmonics Inc | Modifizierte sulfonamidpolymere |
| WO2003037852A1 (en) | 2001-11-01 | 2003-05-08 | Wyeth Holdings Corporation | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| PE20030701A1 (es) | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
| US20040157836A1 (en) * | 2002-10-08 | 2004-08-12 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
| US7491718B2 (en) | 2002-10-08 | 2009-02-17 | Abbott Laboratories | Sulfonamides having antiangiogenic and anticancer activity |
| WO2005021489A2 (en) | 2002-12-23 | 2005-03-10 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
| DE602005017879D1 (de) * | 2004-03-22 | 2010-01-07 | Southern Res Inst | Nichtpeptidinhibitoren von matrixmetalloproteinasen |
| FR2947270B1 (fr) * | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
| FR2947268B1 (fr) | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
| US20140275108A1 (en) | 2013-03-15 | 2014-09-18 | Galderma Research & Development | Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics |
| IL237852A0 (en) | 2015-03-19 | 2016-03-24 | Yeda Res & Dev | Antibodies against amphigoline, medical preparations containing them and their use |
| US20190008828A1 (en) | 2015-12-28 | 2019-01-10 | The U.S.A., As Represented By The Secretary Department Of Health And Human Services | Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells |
| ES2695533T3 (es) | 2016-02-01 | 2019-01-08 | Galderma Res & Dev | Compuestos de bencenosulfonamida, método para su síntesis y uso de los mismos en medicina y cosméticos |
| CA3115038A1 (en) | 2018-10-04 | 2020-04-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Egfr inhibitors for treating keratodermas |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| CA2160139A1 (en) * | 1993-04-07 | 1994-10-13 | Richard Edward Galardy | Synthetic matrix metalloprotease inhibitors and uses thereof |
| US5672598A (en) * | 1995-03-21 | 1997-09-30 | The Procter & Gamble Company | Lactam-containing hydroxamic acids |
-
1997
- 1997-10-08 CN CN97180606A patent/CN1105101C/zh not_active Expired - Fee Related
- 1997-10-08 WO PCT/US1997/018170 patent/WO1998016506A1/en not_active Ceased
- 1997-10-08 NZ NZ335053A patent/NZ335053A/xx unknown
- 1997-10-08 CA CA002268895A patent/CA2268895A1/en not_active Abandoned
- 1997-10-08 EP EP97912674A patent/EP0934259B1/en not_active Expired - Lifetime
- 1997-10-08 AU AU49790/97A patent/AU736134B2/en not_active Ceased
- 1997-10-08 JP JP10518424A patent/JP2001502326A/ja not_active Ceased
- 1997-10-08 KR KR1019990703296A patent/KR20000049198A/ko not_active Abandoned
- 1997-10-08 BR BR9712524-5A patent/BR9712524A/pt not_active Application Discontinuation
- 1997-10-08 AT AT97912674T patent/ATE224364T1/de not_active IP Right Cessation
- 1997-10-08 PT PT97912674T patent/PT934259E/pt unknown
- 1997-10-08 IL IL12914997A patent/IL129149A/xx not_active IP Right Cessation
- 1997-10-08 DK DK97912674T patent/DK0934259T3/da active
- 1997-10-08 DE DE69715647T patent/DE69715647T2/de not_active Expired - Fee Related
- 1997-10-08 ES ES97912674T patent/ES2184069T3/es not_active Expired - Lifetime
- 1997-10-15 AR ARP970104748A patent/AR008676A1/es not_active Application Discontinuation
- 1997-10-15 ZA ZA9709236A patent/ZA979236B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1240424A (zh) | 2000-01-05 |
| AU4979097A (en) | 1998-05-11 |
| ZA979236B (en) | 1999-07-15 |
| DE69715647D1 (en) | 2002-10-24 |
| IL129149A (en) | 2003-10-31 |
| EP0934259A1 (en) | 1999-08-11 |
| KR20000049198A (ko) | 2000-07-25 |
| JP2001502326A (ja) | 2001-02-20 |
| CN1105101C (zh) | 2003-04-09 |
| AR008676A1 (es) | 2000-02-09 |
| DK0934259T3 (da) | 2003-01-27 |
| AU736134B2 (en) | 2001-07-26 |
| IL129149A0 (en) | 2000-02-17 |
| WO1998016506A1 (en) | 1998-04-23 |
| NZ335053A (en) | 2000-10-27 |
| ATE224364T1 (de) | 2002-10-15 |
| EP0934259B1 (en) | 2002-09-18 |
| DE69715647T2 (de) | 2003-02-20 |
| BR9712524A (pt) | 1999-10-19 |
| PT934259E (pt) | 2003-01-31 |
| HK1020720A1 (en) | 2000-05-19 |
| CA2268895A1 (en) | 1998-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2166102T3 (es) | Preparacion y utilizacion de acidos orto-sulfonamidoarilhidroxamicos como inhibidores de las metaloproteinasas matriz y los tace. | |
| AR009990A1 (es) | Acidos orto-sulfonamido heteroaril hidroxamicos biciclicos como inhibidores de la metaloproteinasa de matriz y tace, uso de dichos compuestos para prepararmedicamentos, y composiciones farmaceuticas que los contienen | |
| BR9714350A (pt) | Preparação e uso de ácidos orto-sulfonamido heteroaril hidroxâmicos com inibidores de metaloproteinases de matriz e da tace | |
| DK2720693T3 (en) | CHROMAN-LIKE CYCLIC PRENYLFLAVONOIDS FOR MEDICAL INTERVENTION IN NEUROLOGICAL DISEASES | |
| AR021799A1 (es) | Naftopiranos ciclados en c5-6, su preparacion y composiciones y matrices de (co) polimero que las contienen | |
| ES2184070T3 (es) | Derivados de oximas sustituidas utiles como antagonistas de la neuroquinina. | |
| AR008676A1 (es) | Acidos beta-sulfonamido hidrosamicos como inhibidores de la metaloproteinasa de matriz y tace, uso de los mismos en la preparacion de unmedicamento y una composicion farmaceutica que los contienen | |
| ES2011210T3 (es) | Derivados de gem-difosfonato substituido, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
| NO20012975L (no) | Nye bifenyl og bifenylanaloge forbindelser som integrinantagonister | |
| ES2061077T3 (es) | Metodo para producir un producto intermedio para la preparacion de promedicamentos. | |
| TR200000670T2 (tr) | FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler. | |
| ES2159734T3 (es) | Derivados 2-heteroarilalquenilicos del acido ciclopentano-heptan(en)oico como agentes terapeuticos para el tratamiento de la hipertension ocular. | |
| ES2107212T3 (es) | Derivados de 1,4-benzoxazina como abridores de los canales de potasio. | |
| ES2175155T3 (es) | Cetoacidos aromaticos y sus derivados como inhibidores de las metaloproteinasas matriciales. | |
| Wei et al. | Salidroside promotes the osteogenic and odontogenic differentiation of human dental pulp stem cells through the BMP signaling pathway | |
| MX172079B (es) | Produccion de trazolinonas | |
| Youssef et al. | Amoebicidal thymol analogues against brain-eating amoeba, Naegleria fowleri | |
| ES2029879T3 (es) | Procedimiento para producir derivados de aminas sustituidas. | |
| ES2056073T3 (es) | Aril-aralquil-eteres, procedimientos para su preparacion y composicion farmaceutica que los comprende. | |
| AR246521A1 (es) | Un procedimiento para la preparacion de derivados del cromeno. | |
| IL166103A0 (en) | Pyrrolidine derivatives and their use | |
| UY28647A1 (es) | Compuestos de amida del ácido 3-amino-tieno(2,3-b)piridin-2-carboxílico sustituido y procedimientos para su preparación y sus usos | |
| FI905957A0 (fi) | Foerfarande foer framstaellning av substituerade cyklohexener, som verkar pao det centrala nervsystemet. | |
| ES2172023T3 (es) | Nuevos derivados tetrahidro-piridinicos sustituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| CO2025002334A2 (es) | Derivados arilos tricíclicos, y composiciones y métodos de los mismos |